Table 1.
Subject demographics at baseline and final (after 6 months of therapy) visits
| Exenatide (n = 14) |
Sitagliptin (n = 12) |
Glimepiride (n = 14) |
|||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline | 6 monthsa | Δ | Baseline | 6 monthsa | Δ | Baseline | 6 monthsa | Δ | |
| Age (years) | 57 ± 2 | — | — | 57 ± 3 | — | — | 52 ± 3 | — | — |
| Sex (% female) | 36 | — | — | 33 | — | — | 43 | — | — |
| Race (% African American) | 50 | — | — | 42 | — | — | 64 | — | — |
| Duration of T2D (years) | 3.3 ± 0.6 | — | — | 5.3 ± 1.7 | — | — | 3.4 ± 0.9 | — | — |
| BMI (kg/m2) | 33 ± 2 | 32 ± 2* | −1 ± 0 | 33 ± 1 | 33 ± 1 | 0 ± 0 | 31 ± 2 | 31 ± 2 | 0 ± 1 |
| HbA1c, %b (mmol/mol) | 6.4 ± 0.1 (46) | 6.2 ± 0.1 (44) | −0.2 ± 0.1 | 6.5 ± 0.1 (48) | 6.5 ± 0.2 (48) | −0.01 ± 0.1 | 6.7 ± 0.1 (50) | 6.2 ± 0.2 (44)* | −0.5 ± 0.2 |
| Fasting glucose (mg/dL) | 129 ± 3 | 128 ± 5 | −2 ± 5 | 131 ± 4 | 132 ± 8 | 1 ± 9 | 134 ± 4 | 126 ± 5 | −8 ± 6 |
| Fasting insulin (μU/mL) | 24 ± 6 | 21 ± 3 | −3 ± 4 | 17 ± 2 | 14 ± 2 | −2.6 ± 2 | 17 ± 2 | 15 ± 1.3 | −2 ± 2 |
| Fasting glucagon (pg/mL) | 40 ± 4 | 42 ± 8 | 2 ± 6 | 50 ± 6 | 47 ± 7 | −3 ± 6 | 51 ± 4 | 51 ± 5 | −0.2 ± 4 |
| Total cholesterol (mg/dL) | 168 ± 7 | 157 ± 6 | −10 ± 7 | 159 ± 12 | 162 ± 10 | 4 ± 6 | 172 ± 10 | 168 ± 11 | −4 ± 7 |
| Triglycerides (mg/dL) | 110 ± 15 | 85 ± 9 | −25 ± 14 | 104 ± 17 | 118 ± 20 | 11 ± 10 | 107 ± 18 | 93 ± 11 | −14 ± 16 |
| LDL cholesterol (mg/dL) | 104 ± 5 | 92 ± 6 | −12 ± 6 | 94 ± 10 | 101 ± 9 | 5 ± 6 | 110 ± 7 | 111 ± 11 | 2 ± 7 |
| HDL cholesterol (mg/dL) | 41 ± 2 | 48 ± 3* | 7 ± 2† | 44 ± 5 | 38 ± 2 | −3 ± 1 | 41 ± 3 | 38 ± 2 | −3 ± 2 |
Data are means ± SE.
Δ, change from baseline to 6 months with each value.
aFinal visits after 6 months of therapy were conducted following a 5- to 7-day drug washout.
bTo convert to mmol/mol, multiply by 10.93 and subtract 23.50.
*P < 0.05 when comparing values within each group.
†P < 0.05 when comparing Δ between the exenatide and glimepiride groups.